Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

57.1%

4 terminated/withdrawn out of 7 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT00669422Terminated

ChemoFx® PRO - A Post-Market Data Collection Study

Role: lead

NCT01007890Terminated

Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer

Role: lead

NCT01271959Terminated

A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study

Role: lead

NCT00288275Terminated

Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

Role: lead

NCT01450553Unknown

Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease

Role: lead

NCT01048814Completed

Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases

Role: lead

NCT01049126Completed

Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Assay in Endometrial Cancer Patients

Role: lead

All 7 trials loaded